SYFOVRE™ (pegcetacoplan injection) has been approved by the U.S. Food & Drug Administration (FDA) for people with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a leading cause of devastating central vision loss in people over 55 in developed countries. The newly approved therapy is the first ever approved by the FDA for GA. SYFOVRE slowed the growth of lesions (areas of retinal cell loss) in two Phase 3 clinical trials. In the trials, known as DERBY and OAKS, the treatment was safe and its beneficial effect increased over time. More than 12,000 injections were delivered to trial participants over 24 months.
SYFOVRE will be delivered through an injection into the vitreous, the soft gel in the middle of the eye, once every 25 to 60 days in your ophthalmologists office. Frequency of the injections will be at the doctor’s discretion.
If you have geographic atrophy (GA) associated with dry AMD, consult your retinal specialist to determine if SYFOVRE is appropriate for you.